These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. Christensen RM; Juhl CR; Torekov SS Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641 [TBL] [Abstract][Full Text] [Related]
46. Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice. Heppner KM; Marks S; Holland J; Ottaway N; Smiley D; Dimarchi R; Perez-Tilve D Diabetologia; 2015 Sep; 58(9):2124-32. PubMed ID: 26049402 [TBL] [Abstract][Full Text] [Related]
47. Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms. Kanoski SE; Ong ZY; Fortin SM; Schlessinger ES; Grill HJ Diabetes Obes Metab; 2015 Mar; 17(3):285-93. PubMed ID: 25475828 [TBL] [Abstract][Full Text] [Related]
48. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice. Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728 [TBL] [Abstract][Full Text] [Related]
49. GLP-1R Signaling Directly Activates Arcuate Nucleus Kisspeptin Action in Brain Slices but Does not Rescue Luteinizing Hormone Inhibition in Ovariectomized Mice During Negative Energy Balance. Heppner KM; Baquero AF; Bennett CM; Lindsley SR; Kirigiti MA; Bennett B; Bosch MA; Mercer AJ; Rønnekleiv OK; True C; Grove KL; Smith MS eNeuro; 2017; 4(1):. PubMed ID: 28144621 [TBL] [Abstract][Full Text] [Related]
50. Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity. Lee SJ; Sanchez-Watts G; Krieger JP; Pignalosa A; Norell PN; Cortella A; Pettersen KG; Vrdoljak D; Hayes MR; Kanoski SE; Langhans W; Watts AG Mol Metab; 2018 May; 11():33-46. PubMed ID: 29650350 [TBL] [Abstract][Full Text] [Related]
51. Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy. Wen Y; Wu K; Xie Y; Dan W; Zhan Y; Shi Q Biochem Biophys Res Commun; 2019 Mar; 511(1):79-86. PubMed ID: 30770099 [TBL] [Abstract][Full Text] [Related]
52. Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action. Varin EM; Mulvihill EE; Baggio LL; Koehler JA; Cao X; Seeley RJ; Drucker DJ Cell Rep; 2019 Jun; 27(11):3371-3384.e3. PubMed ID: 31189118 [TBL] [Abstract][Full Text] [Related]
54. Glucagon-Like Peptide-1 Receptor Signaling in the Lateral Dorsal Tegmental Nucleus Regulates Energy Balance. Reiner DJ; Leon RM; McGrath LE; Koch-Laskowski K; Hahn JD; Kanoski SE; Mietlicki-Baase EG; Hayes MR Neuropsychopharmacology; 2018 Feb; 43(3):627-637. PubMed ID: 28920591 [TBL] [Abstract][Full Text] [Related]
55. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. Torekov SS Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921 [No Abstract] [Full Text] [Related]
56. Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system. Kaineder K; Birngruber T; Rauter G; Obermüller B; Eichler J; Münzker J; Al-Zoughbi W; Mautner SI; Torekov SS; Hartmann B; Kotzbeck P; Pieber TR Int J Obes (Lond); 2017 Aug; 41(8):1263-1270. PubMed ID: 28507313 [TBL] [Abstract][Full Text] [Related]
57. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Beiroa D; Imbernon M; Gallego R; Senra A; Herranz D; Villarroya F; Serrano M; Fernø J; Salvador J; Escalada J; Dieguez C; Lopez M; Frühbeck G; Nogueiras R Diabetes; 2014 Oct; 63(10):3346-58. PubMed ID: 24917578 [TBL] [Abstract][Full Text] [Related]
58. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
59. Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy. Roth E; Benoit S; Quentin B; Lam B; Will S; Ma M; Heeley N; Darwish T; Shrestha Y; Gribble F; Reimann F; Pshenichnaya I; Yeo G; Baker DJ; Trevaskis JL; Blouet C Mol Metab; 2021 Jan; 43():101118. PubMed ID: 33221554 [TBL] [Abstract][Full Text] [Related]
60. Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension. Helmstädter J; Frenis K; Filippou K; Grill A; Dib M; Kalinovic S; Pawelke F; Kus K; Kröller-Schön S; Oelze M; Chlopicki S; Schuppan D; Wenzel P; Ruf W; Drucker DJ; Münzel T; Daiber A; Steven S Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):145-158. PubMed ID: 31747801 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]